Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 0
-1.59%-3.35%+52.37%+91.62% 69.54B
-1.34%-0.75%+48.21%+92.23% 64.97B
-4.13%-0.04%+35.02%+10.03% 26.51B
-2.35%-5.75%-12.90%+436.87% 25.89B
-8.37%-12.43%+2.08%-18.39% 25.64B
-0.96%+10.36%+283.06%+429.04% 20.22B
-0.51%+0.23%+35.77%-19.61% 19.98B
-4.45%-6.12%+1.03%+541.83% 15.69B
-1.47%+0.68%+45.51%+142.00% 13.49B
Average -2.52%-1.93%+54.46%+189.51% 31.33B
Weighted average by Cap. -2.49%-1.50%+51.40%+149.56%
Logo Thallion Pharmaceuticals Inc.
Thallion Pharmaceuticals Inc is a Canada-based biotechnology company. The Company develops pharmaceutical products in the areas of infectious disease and oncology. Thallion Pharmaceuticals Inc's lead clinical program, Shigamabs, is a dual antibody product for the treatment of Shiga toxin-producing E. coli bacterial infections and has completed a Phase II clinical trial. The Company is a subsidiary of BELLUS Health.
Employees
-